Lipase Levels and Coronavirus Disease 2019

Sponsor

Uşak University (Other)

Overall Status

Completed

CT.gov ID

NCT05601258

Collaborator

(none)

4,000

Enrollment

Location

15.3

Actual Duration (Months)

261.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Although COVID-19 disease due to Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affects the respiratory tract, heart and coagulation system, symptoms of gastrointestinal system involvement such as abdominal pain, nausea, vomiting and diarrhea are also common.

In this study, it was aimed retrospective analysis of clinical and laboratory data of patients who developed pancreatic injury and acute pancreatitis in the course of COVID 19 disease.

Condition or Disease	Intervention/Treatment	Phase
Pancreatitis Lipase Increased	Other: Age, gender, hospitalization and mortality rates will be compared

Study Design

Study Type:

Observational

Actual Enrollment :

4000 participants

Observational Model:

Case-Control

Time Perspective:

Retrospective

Official Title:

Association Between Pancreatic Lipase Levels and Coronavirus Disease 2019

Actual Study Start Date :

Mar 31, 2020

Actual Primary Completion Date :

Jul 9, 2021

Actual Study Completion Date :

Jul 9, 2021

Arms and Interventions

Arm	Intervention/Treatment
patients with higher lipase level patients with higher lipase levels (higher than the laboratory upper limits) in the course of SARS-CoV-2 infection	Other: Age, gender, hospitalization and mortality rates will be compared Age, gender, hospitalization and mortality rates will be compared
Control patients with normal lipase levels in the course of SARS-CoV-2 infection	Other: Age, gender, hospitalization and mortality rates will be compared Age, gender, hospitalization and mortality rates will be compared

Arm

Intervention/Treatment

patients with higher lipase level

patients with higher lipase levels (higher than the laboratory upper limits) in the course of SARS-CoV-2 infection

Other: Age, gender, hospitalization and mortality rates will be compared

Age, gender, hospitalization and mortality rates will be compared

Control

patients with normal lipase levels in the course of SARS-CoV-2 infection

Other: Age, gender, hospitalization and mortality rates will be compared

Age, gender, hospitalization and mortality rates will be compared

Outcome Measures

Primary Outcome Measures

The frequency of lipase enzyme elevation will be compared [From 31th March 2020 until 9th July 2021]
The mortaliy rate will be compared [From 31th March 2020 until 9th July 2021]

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

All

Inclusion Criteria:

Patients with lipase levels measured during COVID-19

Exclusion Criteria:

Patients with age <18 years Patients with pregnancy Patients whose lipase levels were not measured in the course of COVID-19 Patients with known solid organ malignacy Patients with known hematologic malignacy

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Cevdet Duran	Usak		Turkey	64200

Sponsors and Collaborators

Uşak University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Cevdet Duran, Cevdet Duran, Uşak University

ClinicalTrials.gov Identifier:

NCT05601258

Other Study ID Numbers:

UsakUCevdet3

First Posted:

Nov 1, 2022

Last Update Posted:

Nov 1, 2022

Last Verified:

Oct 1, 2022

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

COVID-19

Pancreatitis

Study Results

No Results Posted as of Nov 1, 2022